Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

The Oncology Institute, Inc. (TOI) had Revenue of $393.41M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$393.41M
Net Income	$-64.66M
Cost of Goods Sold	$339.42M
Gross Profit	$54.00M
Operating Expenses	$453.53M
Operating Income	$-60.12M
Non-Operating Income/Expense	$-4.54M
Pre-Tax Income	$-64.66M
Normalized Pre-Tax Income	$-64.66M
Income after Taxes	$-64.66M
Income from Continuous Operations	$-64.66M
Consolidated Net Income/Loss	$-64.66M
Normalized Income after Taxes	$-64.66M
EBIT	$-60.12M
EBITDA	$-48.03M
Weighted-Average Shares Outstanding (Basic)	75.04M
Weighted-Average Shares Outstanding (Diluted)	75.04M
Earnings per Share (EPS) (Basic)	$-0.71
Earnings per Share (EPS) (Diluted)	$-0.71
Balance Sheet Financials
Current Assets	$112.42M
Property, Plant, and Equipment	$11.89M
Long-Term Assets	$60.30M
Total Assets	$172.72M
Current Liabilities	$52.22M
Long-Term Debt	$93.13M
Long-Term Liabilities	$116.91M
Total Liabilities	$169.13M
Common Equity	$3.59M
Tangible Shareholders Equity	$-18.45M
Shareholders Equity	$3.59M
Common Shares Outstanding	75.74M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-26.54M
Cash Flow from Investing Activities	$46.21M
Cash Flow from Financial Activities	$-3.49M
Beginning Cash	$33.49M
End Cash	$49.67M
Increase/Decrease in Cash	$16.18M
Stock-Based Compensation	$11.15M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.15
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.96
Debt to Equity Ratio	25.95
Gross Margin	13.73%
Operating Margin	-15.28%
EBIT Margin	-15.28%
EBITDA Margin	-12.21%
Pre-Tax Profit Margin	-16.44%
Profit Margin	-16.44%
Free Cash Flow	$-30.33M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	2.28
Inventory Turnover	33.81
Receiveable Turnover	8.08
Days Sales in Receivables	45.17
Return on Equity	-1801.71%
Return on Tangible Equity	350.46%
Return on Assets	-37.44%
Return on Investments	-66.86%
Book Value Per Share	$0.05
Free Cash Flow per Share	$-0.40
Operating Cash Flow per Share	$-0.35

Data from Zacks Investment Research, Inc.